Introduction: What they say
A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.” This research paper was published, in the 29 March 2012 issue of the journal “Nature” [One of the best research journals in Science, with an I.F of 43 plus], by Prof.Burris TP, Solt LA and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Mechanistic insights into how yoga therapy aids in control of body weight, energy homeostasis and TIIDM: Yoga therapy increases REV-ERB and its downstream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene
From significance of the study to public health relevance:
Given that: (1) more than half a billion adults are obese worldwide ; (2) obesity is more prevalent in western countries than in asian countries; (3) obesity results in deregulated blood pressure, cholesterol, triglycerides and insulin sensitivity; and the risks of coronary heart disease, ischemic stroke and TII diabetes mellitus(TIIDM) increase ; (4) more than 422 million people worldwide are affected by Diabetes mellitus (DM); (5) Diabetes is going to be one of the top 10 causes of death by 2030; (6) the life-long painful injection/drug treatment is required to treat DM; and (7) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, obesity-associated diseases, including diabetes.
What is known?
Prof.Burris’s research team has recently shown that administration of REV-ERB ligands:(1) regulates circadian behaviour and the circadian pattern of core clock gene;(2) alters the circadian pattern of expression of metabolic genes in liver, skeletal muscle, and adipose tissue; (3) increases energy expenditure; (4) inhibits lipid accumulation; (4) decreases obesity; (5) improves dyslipidemia; and (6) reduces hyperglycemia, suggesting that increasing the expression of REV-ERB may promote weight loss, augment insulin sensitivity, improve dyslipidemia and alleviate Obesity-associated TIIDM.
From Research findings to Therapeutic opportunity:
Yoga is practiced in India for over 7000+ years, however, the mechanistic basis of its therapeutic effect, at the molecular level, in attenuating insulin resistance, the development of diabetes, and obesity, among others, remains largely obscure for centuries.
This study provides, for the first time, mechanistic insights into how yoga therapy, practiced all over the world today, promotes insulin secretion, and insulin sensitivity, and thereby attenuates the development of metabolic disease.
First, Thioredoxin-interacting protein (TXNIP), one of the top glucose-induced gene, has been shown to promote insulin resistance and cause diabetes, while REV-ERB, a circadian protein known to play a role in metabolism, has been shown to attenuate hyperglycemia and obesity.
Second, TXNIP inhibitor has been shown to protect against autoimmune diabetes, while REV-ERB activators have been shown to negatively regulate autoimmune diseases and Obesity-associated TIIDM.
This study presented here suggests, for the first time, that Yoga therapy, by increasing the expression of its target gene, it may increase the expression of REV-ERB and decrease the expression of TXNIP (Fig.1). Thereby, it may: (1) normalize circadian pattern of metabolic genes; (2) augment energy expenditure; (3) inhibit lipid accumulation; (4) promote weight loss; (5) ameliorate dyslipidemia; and (6) inhibit hyperglycemia (Figs.1-2).
Thus, yoga therapy, either alone or in combination with other drugs” may be used: (i) as a weight-loss medication; (ii) to treat Obesity-associated TIIDM; (iii) to treat sleep disorders (Figs.3-4).
Thus, yoga therapy may be used to treat obesity and diabetes. Given the mechanistic basis, that was based on proven experimental results, published at the highest level, medical practitioners, & diabetologists may strongly recommend their patients to practice yoga.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does yoga therapy increase the expression of REV-ERB?
Amount: $500#
# Research cooperation
For purchase and payment details, you may reach us at info@genomediscovery.org
References:
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., Mechanistic insights into how yoga therapy aids in control of body weight, energy homeostasis and TIIDM: Yoga therapy increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 22/June/2019, 11.29 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite, drop us a line at info@genomediscovery.org
